ATOX1 and cancer: Interestingly, it has been found that some cancer cell lines with the higher levels of the Atox1 protein have correspondingly higher resistance to the cisplatin agent than the cell lines with lower levels of the Atox1 protein [27,28], which means that the binding of cispaltin agent to the Atox1 protein can resist the activity of the cisplatin agent in the cancer treatment.